List view / Grid view
1 December 2014 | By ABIVAX
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.,,
25 November 2014 | By LaVison BioTec
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Peter Friedl and his imaging of cancer growth using intravital microscopy...
25 November 2014 | By The Lead South Australia
New drugs and treatment strategies will be developed from research that provides a new understanding of how bacterial toxins target human cells...
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
24 November 2014 | By MRC Technology / Yabao Pharmaceuticals
MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...
21 November 2014 | By The Institute of Cancer Research
Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London
19 November 2014 | By Diamond
Structure of EzrA protein could help identify new antibiotic targets...
19 November 2014 | By BerGenBio
BerGenBio AS, an oncology biopharmaceutical company, announces that the US Food and Drug Administration (FDA) has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML)...
19 November 2014 | By Nosopharm
These high-profile experts will help with the quick and safe launch of the preclinical development program for a new class of antibiotics...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
13 November 2014 | By Amgen
Thirteen presentations include new analyses of PCSK9 inhibitor at upcoming American Heart Association Scientific sessions...
12 November 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration with the National Cancer Centre Singapore (NCCS)...
12 November 2014 | By Enterome
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases...
11 November 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced that it has selected research partners for its 2014 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project...
7 November 2014 | By Felicitex Therapeutics and Selvita
Felicitex Therapeutics and Selvita have announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors...
